Designing anti-diabetic β-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis

Biotechnology Progress

Volumn 32, Issue 2, 2016, Pages 501-509

  Mooranian, Armin ^a   Negrulj, Rebecca ^a   Al Salami, Hani ^a   Morahan, Grant ^b   Jamieson, Emma ^b  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bile acid; Biomaterials; Microencapsulation; Pancreatic cells; Type 1 diabetes

Indexed keywords

AMINO ACIDS; BIOACTIVITY; BIOMATERIALS; BODY FLUIDS; CELLS; METABOLISM; MICROENCAPSULATION; MICROSTRUCTURE; MORPHOLOGY; POLYELECTROLYTES; SODIUM ALGINATE;

ANTI DIABETICS; ANTI-INFLAMMATORIES; BILE ACID; PANCREATIC BETA CELLS; POLY L ORNITHINES; STRUCTURAL CHARACTERISTICS; TYPE 1 DIABETES; URSODEOXYCHOLIC ACID;

CYTOLOGY;

ANTIDIABETIC AGENT; BILE ACID; CYTOKINE; POLYALLYLAMINE; POLYAMINE; POLYSTYRENE DERIVATIVE; SULFONIC ACID DERIVATIVE;

ANIMAL; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG FORMULATION; ENERGY METABOLISM; METABOLISM; MOUSE; PANCREAS ISLET BETA CELL; SYNTHESIS;

ANIMALS; BILE ACIDS AND SALTS; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DRUG COMPOUNDING; DRUG DESIGN; ENERGY METABOLISM; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MICE; POLYAMINES; POLYSTYRENES; SULFONIC ACIDS;

EID: 84956855482     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.2223     Document Type: Article

References (40)

1. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378:169-181.
2. Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013;36:1047-1055.
3. Negrulj R, Mooranian A, Al-Salami H. Potentials and limitations of bile acids in type 2 diabetes mellitus: applications of microencapsulation as a novel oral delivery system. J Endocrinol Diabetes Mellitus. 2013;1:49-59.
4. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144:768-773.
5. Beck J, Angus R, Madsen B, Britt D, Vernon B, Nguyen KT. Islet encapsulation: strategies to enhance islet cell functions. Tissue Eng. 2007;13:589-599.
6. Puri S, Hebrok M. Diabetic beta cells: to be or not to be? Cell. 2012;150:1103-1104.
7. Claiborn KC, Stoffers DA. Toward a cell-based cure for diabetes: advances in production and transplant of beta cells. Mt Sinai J Med. 2008;75:362-371.
8. Baş VN, Çetinkaya S, Ağladioğlu SY, Kendirici HN, Bilgili H, Yildirim N, Aycan Z. Insulin oedema in newly diagnosed type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 2010;2:46-48.
9. Fineberg SE, Anderson JH. Complications of Insulin Therapy. International Textbook of Diabetes Mellitus. New York: John Wiley & Sons, Ltd; 2003.
10. Rokstad AM, Lacik I, de Vos P, Strand BL. Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation. Adv Drug Deliv Rev. 2014;6768C:111-130.
11. Weir GC. Islet encapsulation: advances and obstacles. Diabetologia. 2013;56:1458-1461.
12. Mooranian A, Negrulj R, Chen-Tan N, Fakhoury M, Arfuso F, Jones F, Al-Salami H. Advanced bile acid-based multi-compartmental microencapsulated pancreatic beta-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. Artif Cells Nanomed Biotechnol. 2014;1-8.
13. Mooranian A, Negrulj R, Arfuso F, Al-Salami H. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells. Artif Cells Nanomed Biotechnol. 2014;1-7.
14. Wong H, Chang TM. The microencapsulation of cells within alginate poly-L-lysine microcapsules prepared with the standard single step drop technique: histologically identified membrane imperfections and the associated graft rejection. Biomater Artif Cells Immobilization Biotechnol. 1991;19:675-686.
15. Orive G, Hernández RM, Rodríguez Gascón A, Calafiore R, Chang TM, de Vos P, Hortelano G, Hunkeler D, Lacík I, Pedraz JL. History, challenges and perspectives of cell microencapsulation. Trends Biotechnol. 2004;22:87-92.
16. Schmidt JJ, Rowley J, Kong HJ. Hydrogels used for cell-based drug delivery. J Biomed Mater Res A. 2008;87:1113-1122.
17. Bhatia SR, Khattak SF, Roberts SC. Polyelectrolytes for cell encapsulation. Curr Opin Colloid Interface Sci. 2005;10:45-51.
18. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur TK, Mikov M, Lalic-Popovic M, Stojancevic M, Golocorbin-Kon S, Al-Salami H. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol. 2015;20:702-709.
19. Mooranian A, Negrulj R, Arfuso F, Al-Salami H. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015;1-12.
20. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur T, Mikov M, Lalic-Popovic M, Stojančević M, Golocorbin-Kon S, Al-Salami H. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov. 2014;1-8.
21. Hamaguchi K, Gaskins HR, Leiter EH. NIT-1, a pancreatic beta-cell line established from a transgenic NOD/Lt mouse. Diabetes. 1991;40:842-849.
22. Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur TK, Mikov M, Golocorbin-Kon S, Fakhoury M, Watts GF, Matthews V, Arfuso F, Al-Salami H. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Dev Ther. 2014;8:1221-1230.
23. Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, Mikov M, Golocorbin-Kon S, Fakhoury M, Arfuso F, Al-Salami H. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Des Dev Ther. 2014;8:1003-1012.
24. Mooranian A, Negrulj R, Chen-Tan N, Watts GF, Arfuso F, Al-Salami H. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Dev Ther. 2014;8:1673-1683.
25. Mooranian A, Negrulj R, Arfuso F, Al-Salami H. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic beta-cell line. Artif Cells Nanomed Biotechnol. 2015;1-12.
26. Negrulj R, Mooranian A, Chen-Tan N, Al-Sallami HS, Mikov M, Golocorbin-Kon S, Fakhoury M, Watts GF, Arfuso F, Al-Salami H. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artif Cells Nanomed Biotechnol. 2015;1-8.
27. Lee YY, Hong SH, Lee YJ, Chung SS, Jung HS, Park SG, Park KS. Tauroursodeoxycholate (TUDCA), chemical chaperone, enhances function of islets by reducing ER stress. Biochem Biophys Res Commun. 2010;397:735-739.
28. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009;50:1721-1734.
29. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda, Md). 2009;24:325-331.
30. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851-860.
31. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab. 2010;21:261-267.
32. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, Reinecke M. Mechanisms of β-cell death in type 2 diabetes. Diabetes. 2005;54:S108-SS13.
33. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol. 2005;77:587-597.
34. Thomas HE, Angstetra E, Fernandes RV, Mariana L, Irawaty W, Jamieson EL, Dudek NL, Kay TW. Perturbations in nuclear factor-kappaB or c-Jun N-terminal kinase pathways in pancreatic beta cells confer susceptibility to cytokine-induced cell death. Immunol Cell Biol. 2006;84:20-27.
35. de Vos P, de Haan BJ, Kamps JA, Faas MM, Kitano T. Zeta-potentials of alginate-PLL capsules: a predictive measure for biocompatibility? J Biomed Mater Res a. 2007;80:813-819.
36. Labhasetwar VD, Dorle AK. A study on the zeta potential of microcapsules during ageing. J Microencapsul. 1991;8:83-85.
37. Mooranian A, Negrulj R, Al-Salami H. The effects of ionic gelation- vibrational jet flow technique in fabrication of microcapsules incorporating β-cell: applications in type-1 diabetes. Curr Diabetes Rev. 2015; http://www.eurekaselect.com/node/138109/article, In press.
38. Mooranian A, Negrulj R, Al-Salami H. The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable β-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies. Drug Deliv Transl Res. 2015;1-7.
39. Mooranian A, Negrulj R, Al-Salami H. Viability and topographical analysis of microencapsulated β-cells exposed to a biotransformed tertiary bile acid: an ex vivo study. Int J Nano Biomater. 2016; In press.
40. Mooranian A, Negrulj R, Al-Salami H. The influence of stabilized deconjugated ursodeoxycholic acid on polymer-hydrogel system of transplantable NIT-1 cells. Pharm Res. 2016; In press.